External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EASL Liver Cancer Summit 2021

-
Coming soon
03:30 PM
Duration 4mins Virtual
IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase 3 study of atezolizumab▼ (atezo) + bevacizumab▼ (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
RS Finn, S Qin, M Ikeda, P Galle, M Ducreux, TY Kim, HY Lim, M Kudo, V Breder, P Merle, A Kaseb, D Li, W Verret, H Shao, J Liu, L Li, AX Zhu, AL Cheng

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar